Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.